If you have been reading about Pharmacokinetics and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-12. Numbers and descriptions here follow the published literature rather than marketing material.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic heptapeptide | Synthetic analogue of alpha-MSH |
| Molecular formula | C50H68N14O10 | Acetate salt form commonly reported |
| Molecular mass | ~1025 Da | Monoisotopic value near 1025.2 |
| Key structural motif | Lactam bridge | Asp side chain to Lys side chain |
| Solid appearance | White to off-white powder | Lyophilised and hygroscopic |
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
Tigecycline can treat complicated skin and structure infections caused by: Escherichia coli, vancomycin-susceptible Enterococcus faecalis, methicillin-resistant Staphylococcus aureus (MRSA), Streptococcus agalactiae, Streptococcus anginosus grp., Streptococcus pyogenes, Enterobacter cloacae, Klebsiella pneumoniae, and Bacteroides fragilis. Tigecycline is indicated for the treatment of complicated intra-abdominal infections caused by: Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, vancomycin-susceptible Enterococcus faecalis, methicillin-resistant Staphylococcus aureus (MRSA), Streptococcus anginosus grp., Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Clostridium perfringens, and Peptostreptococcus micros. Tigecycline may be used for treatment of community-acquired bacterial pneumonia caused by: penicillin-susceptible Streptococcus pneumoniae, Haemophilus influenzae that does not produce Beta-lactamase and Legionella pneumophila. Tigecycline is given intravenously and has activity against a variety of Gram-positive and Gram-negative bacterial pathogens, many of which are resistant to existing antibiotics. Tigecycline successfully completed phase III trials in which it was at least equal to intravenous vancomycin and aztreonam to treat complicated skin and skin structure infections, and to intravenous imipenem and cilastatian to treat complicated intra-abdominal infections.
In 2008, 2K Games confirmed that a PlayStation 3 version of the game was in development by 2K Marin. On July 3, 2008, 2K Games announced a partnership with Digital Extremes and said that the PlayStation 3 version is being developed by 2K Marin, 2K Boston, 2K Australia, and Digital Extremes. Jordan Thomas was the director for the PlayStation 3 version. While there were no graphical improvements to the game over the original Xbox 360 version, the PlayStation 3 version offered the widescreen option called "horizontal plus", introduced via a patch on the 360 version, while cutscene videos were of a much higher resolution than in the DVD version. Additional add-on content was also released exclusively for the PlayStation 3 version. One addition was "Survivor Mode", in which the enemies were made tougher, and Vita-Chambers provided less of a health boost when used, forcing the player to be more creative in approaching foes and to rely more on the less-used plasmids in the game. BioShock also supports Trophies and PlayStation Home. A demo version was released on the PlayStation Store on October 2, 2008. The game was released for PlayStation 3 on October 17, 2008, internationally and on October 21 in North America. An update for the PlayStation 3 version was released on November 13, 2008, to fix some graphical problems and occasions where users experienced a hang and were forced to reset the console. This update also incorporated the "Challenge Rooms" and "New Game Plus" features.
=== Role in tumor growth === Endothelial progenitor cells are likely important in tumour growth and are thought to be critical for metastasis and the angiogenesis. A large amount of research has been done on CFU-Hill bone marrow-derived putative EPCs. Ablation of the endothelial progenitor cells in the bone marrow lead to a significant decrease in tumour growth and vasculature development. This indicates that endothelial progenitor cells present novel therapeutic targets. Inhibitor of DNA Binding 1 (ID1) has been used as a marker for these cells; this allows for tracking EPCs from the bone marrow to the blood to the tumour-stroma and even incorporated in tumour vasculature. Recently it has been found that miRNAs regulate EPC biology and tumour angiogenesis. This work by Plummer et al. found that in particular targeting of the miRNAs miR-10b and miR-196b led to significant defects in angiogenesis-mediated tumor growth by decreasing the mobilization of proangiogenic EPCs to the tumour. These findings indicate that directed targeting these miRNAs in EPCs may result in a novel strategy for inhibiting tumor angiogenesis. Studies have shown ECFCs and human umbilical vein endothelial cells (HUVECs) to have a capacity for tumor migration and neoangiogenesis even greater than that of other CD34+ hematopoietic cells when implanted in immunodeficient mice, suggesting the endothelial progenitors play a key role, but further supporting the importance of both cell types as targets for pharmacological therapy.
Small, hand-pumped reverse osmosis filters were originally developed for the military in the late 1980s for use as survival equipment, for example, to be included with inflatable rafts on aircraft. Civilian versions are available. Instead of using the static pressure of a water supply line to force the water through the filter, pressure is provided by a hand-operated pump. These devices can generate drinkable water from seawater. The Portable Aqua Unit for Lifesaving ("PAUL") is a portable ultrafiltration-based membrane water filter for humanitarian aid. It allows the decentralized supply of clean water in emergency and disaster situations for about 400 persons per unit per day. The filter is designed to function with neither chemicals nor energy nor trained personnel.
=== Premixed === Appropriate patient selection is an essential component of successful premixed insulin therapy. Kalra was the lead author of a comprehensive review developed with collaborators from more than 25 countries. He has also published extensively on the use of premixed insulin during Ramadan and on its role in special situations, from initiation to intensification. He has also published updates on premixed insulins, including real-world evidence regarding newer co-formulations.
Sources: en.wikipedia.org
Rapid reactions can create bioconjuctions and create high concentrations with low amounts of reactants. Contrarily slow kinetic reactions like aldehyde and ketone condensation while effective require a high concentration making it cost inefficient.
Lasers can cause biological damage due to the properties of their radiation and their sometimes extremely concentrated electromagnetic power. For this reason, lasers must be labeled with standardized warnings depending on the laser class. The classification is based on the DIN standard EN 60825-1, which distinguishes between ranges of wavelengths and exposure times that lead to characteristic injuries and injury thresholds for power or energy density. The CO2-Laser was developed in 1964 by the Indian electrical engineer and physicist Chandra Kumar Naranbhai Patel (*1938) at the same time as the Nd:YAG laser (neodymium-doped yttrium aluminum garnet laser) at Bell Laboratories by LeGrand Van Uitert (1922-1999) and Joseph E. Geusic (*1931) and the Er:YAG laser (erbium-doped yttrium aluminum garnet laser) and has been used in dentistry since the early 1970s. In the hard laser field, two systems in particular are emerging for use in the oral cavity: the CO2 laser for use in soft tissue and the Er:YAG laser for use in dental hard and soft tissue. The goal of soft laser treatment is to achieve biostimulation with low energy densities. The Commission on Radiological Protection strongly recommends that the possession and purchase of class 3B and 4 laser pointers be regulated by law to prevent misuse. This is due to the increase in dangerous dazzle attacks caused by high-power laser pointers. In addition to pilots, these include truck and car drivers, train operators, soccer players, referees, and even spectators at soccer games.
== Data analysis == CyTOF mass cytometry data is recorded in tables that list, for each cell, the signal detected per channel, which is proportional to the number of antibodies tagged with the corresponding channel's isotope bound to that cell. These data are formatted as FCS files, which are compatible with traditional flow cytometry software. Due to the high-dimensional nature of mass cytometry data, novel data analysis tools have been developed as well. Imaging Mass Cytometry data analysis has its specificity due to different nature of data obtained. In terms of data analysis, both IMC and CyTOF generate large datasets with high dimensionality that require specialized computational methods for analysis. However, data generated by IMC can be more challenging to analyze due to additional data complexity and need for specific tools and pipelines specific for digital image analysis, whereas the data generated by CyTOF is generally analyzed using conventional flow cytometry software. A comprehensive overview of IMC data analysis techniques has been given by Milosevic in.
=== Major players === In terms of companies engaging directly in logistics, the sector in SA is highly competitive, with no dominant players. Among companies operating in the market are SA-based Transnet, UAE-based DP World (including its SA subsidiary Imperial Logistics), Switzerland-based Kuehne+Nagel, German-based DHL Group, and Denmark-based DSV (including German subsidiary DB Schenker).
Sources: en.wikipedia.org
These ranged from deformed jaws to cyclopia. After decades of research, in the 1980s, the compound responsible for these deformities was identified as the alkaloid 11-deoxyjervine, later renamed to cyclopamine.
In August 2026, Kyle Hyndman and Alberto Bisin published a replication in Psychological Science of Study 2 from Ariely and Klaus Wertenbroch's 2002 article "Procrastination, Deadlines, and Performance: Self-Control by Precommitment". Their newly collected data did not reproduce the original results: changes in deadline conditions had negligible effects on the three performance measures and several survey measures, and evenly spaced externally imposed deadlines were not especially effective at reducing procrastination. On August 31, 2026, Data Colada researchers Uri Simonsohn, Joe Simmons, and Leif Nelson published an analysis of spreadsheet files that Hyndman said he had received from Ariely's MIT email account in 2006; they reported duplicated observations and several other statistical patterns that they considered inconsistent with genuine data and concluded that the data for Study 2 had been tampered with or fabricated. Ariely had stated earlier that month that he had been informed that the data underlying the paper contained "serious anomalies", that the surviving documentary record and his memory were insufficient to resolve the questions raised, and that he and Wertenbroch were cooperating with the journal's review and retraction processes. Data Colada reported that Wertenbroch had asked the editor to retract the 2002 article, and it was retracted on September 2, 2026.
== Phytoestrogens == Most studies of phytoestrogens in soy have identified the isoflavones genistein and daidzein as its principal phytoestrogenic substances. For several soy flour samples analyzed by various persons using high-performance liquid chromatography, daidzein content ranged from 226 to 2100 micrograms per gram, and genistein content ranged from 478 to 1123 micrograms per gram. For four analyses of defatted soy meal, the concentrations were 616 and 753 micrograms per gram, respectively; for one analysis of full-fat soybean meal (whole), concentrations were 706 and 1000 micrograms per gram, respectively. On a dry-matter basis, defatting causes an increase in phytoestrogen concentration. This can be largely explained by the removal of oil mass. Although reproductive physiology of sheep is particularly sensitive to phytoestrogens, soybean meal supplementation of ewe lambs or ewes on pasture in some studies has been found to have no detrimental effect on reproductive performance.
Sources: en.wikipedia.org
PT-141 was the development code used for bremelanotide during its preclinical and early clinical programme. The peptide is now generally referred to by its international nonproprietary name.
The two compounds share the same cyclic core and are both non-selective melanocortin agonists. They differ chiefly at the C-terminus, where bremelanotide carries a free carboxylic acid and melanotan II a terminal amide.
Receptor binding profiles are well characterised in vitro, but the downstream pathway linking MC4R activation to behavioural effects is not fully mapped. Several intermediate neural circuits have been proposed without definitive confirmation.
It primarily activates specific subtypes in the melanocortin receptor family. These receptors are G protein-coupled and mediate signaling mainly within the central nervous system.